Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 11/2010

01-11-2010 | Correspondence

Plasma Anti-Xa Monitoring for Low-Molecular-Weight Heparins in Patients with Chronic Kidney Disease

Authors: Maurizio Gallieni, Alma Martini, Antonio Granata, Maria Fusaro

Published in: Clinical Pharmacokinetics | Issue 11/2010

Login to get access

Excerpt

We read with great interest the article by Al Sallami et al.,[1] indicating that routine plasma anti-Xa monitoring is required for better management of patients treated with low-molecular-weight heparins (LMWHs). We fully agree with their message, supported by data derived from the literature and by their approach through modelling and simulation, and we would like to expand the concept to focus on patients with different degrees of chronic kidney disease. …
Literature
1.
Al-Sallami HS, Barras MA, Green B, et al. Routine plasma anti-Xa monitoring is required for low-molecular-weight heparins. Clin Pharmacokinet 2010 Sep 1; 49(9): 567–71PubMedCrossRef
2.
Gallieni M, Cozzolino M, Ronga C, et al. Low-molecular-weight heparins should be used with caution in patients with chronic kidney disease. Nature Clin Pract Nephrol 2008 Sep; 4(9): 488–9CrossRef
3.
Lim W, Dentali F, Eikelboom JW, et al. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006 May 2; 144(9): 673–84PubMed
4.
Barras MA, Duffull SB, Atherton JJ, et al. Individualized compared with conventional dosing of enoxaparin. Clin Pharmacol Ther 2008 Jun; 83(6): 882–8PubMedCrossRef
5.
Barras MA, Duffull SB, Atherton JJ, et al. Individualized dosingof enoxaparin for subjects with renal impairment is superior to conventional dosing at achieving therapeutic concentrations. Ther Drug Monit 2010 Aug; 32(4): 482–8PubMedCrossRef
6.
Farooq V, Hegarty J, Chandrasekar T, et al. Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. Am J Kidney Dis 2004 Mar; 43(3): 531–7PubMedCrossRef
7.
Gerlach AT, Pickworth KK, Seth SK, et al. Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy 2000 Jul; 20(7): 771–5PubMedCrossRef
8.
Guillet B, Simon N, Sampol JJ, et al. Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. Nephrol Dial Transplant 2003 Nov; 18(11): 2348–53PubMedCrossRef
9.
Stratta P, Karvela E, Canavese C, et al. Structure-activity relationships of low molecular weight heparins expose to the risk of achieving inappropriate targets in patients with renal failure. Curr Med Chem 2009; 16(23): 3028–40PubMedCrossRef
10.
Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009 May 5; 150(9): 604–12PubMed
11.
12.
Stevens LA, Nolin TD, Richardson MM, et al. Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney Dis 2009 Jul; 54(1): 33–42PubMedCrossRef
Metadata
Title
Plasma Anti-Xa Monitoring for Low-Molecular-Weight Heparins in Patients with Chronic Kidney Disease
Authors
Maurizio Gallieni
Alma Martini
Antonio Granata
Maria Fusaro
Publication date
01-11-2010
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 11/2010
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.2165/11534810-000000000-00000

Other articles of this Issue 11/2010

Clinical Pharmacokinetics 11/2010 Go to the issue

Review Article

Pharmacokinetic and Pharmacodynamic Perspectives on the Clinical Drug Development of Panitumumab

Review Article

Oseltamivir in Seasonal, Avian H5N1 and Pandemic 2009 A/H1N1 Influenza

Current Opinion

A Quantitative Framework and Strategies for Management and Evaluation of Metabolic Drug-Drug Interactions in Oncology Drug Development

Original Research Article

Fluoxetine Disposition in Patients with Chronic Hepatitis C Treated with Interferon-α